Independently ligating CD38 and FcγRIIB relays a dominant negative signal to B cells

Alyce M. Oliver, J. Christopher Grimaldi, Maureen C. Howard, John F. Kearney

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

CD38 is expressed on a variety of hematopoietic cells and has a unique enzymatic activity that converts nicotinamide adenine dinucleotide (NAD) into cyclic ADP-ribose (cADPR) and then into ADPR. CD38 is expressed at increasingly higher levels on B cells at each stage of B cell differentiation, and is then down-regulated on germinal center B cells and mature plasma cells. Crosslinking of CD38 on the surface of mature, resting B cells induces B-cell proliferation, which is enhanced by co-signals such as IL-4 and LPS. CD38-induced proliferation is abrogated by FcγRIIB ligation and this inhibition can be effected by the addition of anti-FcγRII Ab midway through a 48 h in vitro culture indicating that it delivers a potent negative signal to CD38 activated B cells. The suppressive signal was shown to occur through the FcγRIIB because CD38-induced B-cell activation was not inhibited by the ligation of FcγRIIB in FcγRII-deficient B cells. These results indicate that FcγRIIB can act as a regulatory molecule that modulates CD38 signals in vivo.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalHybridoma
Volume18
Issue number2
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

B-Lymphocytes
Ligation
Cyclic ADP-Ribose
Germinal Center
Plasma Cells
Interleukin-4
NAD
Cell Differentiation
Cell Proliferation

ASJC Scopus subject areas

  • Immunology
  • Genetics

Cite this

Independently ligating CD38 and FcγRIIB relays a dominant negative signal to B cells. / Oliver, Alyce M.; Grimaldi, J. Christopher; Howard, Maureen C.; Kearney, John F.

In: Hybridoma, Vol. 18, No. 2, 01.01.1999, p. 113-119.

Research output: Contribution to journalArticle

Oliver, Alyce M. ; Grimaldi, J. Christopher ; Howard, Maureen C. ; Kearney, John F. / Independently ligating CD38 and FcγRIIB relays a dominant negative signal to B cells. In: Hybridoma. 1999 ; Vol. 18, No. 2. pp. 113-119.
@article{d866f333aa3b4cf7bcd74d34557fe44f,
title = "Independently ligating CD38 and FcγRIIB relays a dominant negative signal to B cells",
abstract = "CD38 is expressed on a variety of hematopoietic cells and has a unique enzymatic activity that converts nicotinamide adenine dinucleotide (NAD) into cyclic ADP-ribose (cADPR) and then into ADPR. CD38 is expressed at increasingly higher levels on B cells at each stage of B cell differentiation, and is then down-regulated on germinal center B cells and mature plasma cells. Crosslinking of CD38 on the surface of mature, resting B cells induces B-cell proliferation, which is enhanced by co-signals such as IL-4 and LPS. CD38-induced proliferation is abrogated by FcγRIIB ligation and this inhibition can be effected by the addition of anti-FcγRII Ab midway through a 48 h in vitro culture indicating that it delivers a potent negative signal to CD38 activated B cells. The suppressive signal was shown to occur through the FcγRIIB because CD38-induced B-cell activation was not inhibited by the ligation of FcγRIIB in FcγRII-deficient B cells. These results indicate that FcγRIIB can act as a regulatory molecule that modulates CD38 signals in vivo.",
author = "Oliver, {Alyce M.} and Grimaldi, {J. Christopher} and Howard, {Maureen C.} and Kearney, {John F.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1089/hyb.1999.18.113",
language = "English (US)",
volume = "18",
pages = "113--119",
journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",
issn = "2167-9436",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Independently ligating CD38 and FcγRIIB relays a dominant negative signal to B cells

AU - Oliver, Alyce M.

AU - Grimaldi, J. Christopher

AU - Howard, Maureen C.

AU - Kearney, John F.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - CD38 is expressed on a variety of hematopoietic cells and has a unique enzymatic activity that converts nicotinamide adenine dinucleotide (NAD) into cyclic ADP-ribose (cADPR) and then into ADPR. CD38 is expressed at increasingly higher levels on B cells at each stage of B cell differentiation, and is then down-regulated on germinal center B cells and mature plasma cells. Crosslinking of CD38 on the surface of mature, resting B cells induces B-cell proliferation, which is enhanced by co-signals such as IL-4 and LPS. CD38-induced proliferation is abrogated by FcγRIIB ligation and this inhibition can be effected by the addition of anti-FcγRII Ab midway through a 48 h in vitro culture indicating that it delivers a potent negative signal to CD38 activated B cells. The suppressive signal was shown to occur through the FcγRIIB because CD38-induced B-cell activation was not inhibited by the ligation of FcγRIIB in FcγRII-deficient B cells. These results indicate that FcγRIIB can act as a regulatory molecule that modulates CD38 signals in vivo.

AB - CD38 is expressed on a variety of hematopoietic cells and has a unique enzymatic activity that converts nicotinamide adenine dinucleotide (NAD) into cyclic ADP-ribose (cADPR) and then into ADPR. CD38 is expressed at increasingly higher levels on B cells at each stage of B cell differentiation, and is then down-regulated on germinal center B cells and mature plasma cells. Crosslinking of CD38 on the surface of mature, resting B cells induces B-cell proliferation, which is enhanced by co-signals such as IL-4 and LPS. CD38-induced proliferation is abrogated by FcγRIIB ligation and this inhibition can be effected by the addition of anti-FcγRII Ab midway through a 48 h in vitro culture indicating that it delivers a potent negative signal to CD38 activated B cells. The suppressive signal was shown to occur through the FcγRIIB because CD38-induced B-cell activation was not inhibited by the ligation of FcγRIIB in FcγRII-deficient B cells. These results indicate that FcγRIIB can act as a regulatory molecule that modulates CD38 signals in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0033033477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033033477&partnerID=8YFLogxK

U2 - 10.1089/hyb.1999.18.113

DO - 10.1089/hyb.1999.18.113

M3 - Article

C2 - 10380010

AN - SCOPUS:0033033477

VL - 18

SP - 113

EP - 119

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

SN - 2167-9436

IS - 2

ER -